§ Federal grant opportunity · HT942526VRPCTA
DoW Vision, Clinical Trial Award
Teresa M Parker-Reeser Grants Officer is accepting applications for DoW Vision, Clinical Trial Award. The deadline is November 12, 2026 and the published award range is Award amount not published.
Key facts
- Funder
- Teresa M Parker-Reeser Grants Officer
- Application deadline
- November 12, 2026
- Award range
- Award amount not published
- Eligibility
- Eligibility criteria are published in the funding opportunity announcement.
- Geography
- United States
- Focus areas
- Research
- Opportunity number
- HT942526VRPCTA
Program overview
Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of service-connected eye injury and visual dysfunction. Research must align with at least one of the FY26 VRP Focus Areas . Distinctive Features: · For interventions that require Investigational New Drug (IND)/Investigational Device Exemption (IDE) or equivalent regulatory authorizations for clinical testing, the IND/IDE application or equivalent must be submitted to the relevant Regulatory Agency by the CTA application submission deadline. In addition, applicants must provide documentation of communication from the Regulatory Agency indicating that the IND/IDE or equivalent is active/safe to proceed by March 1, 2027, in order for the CTA application to be considered for funding. Refer to Attachment 7: Regulatory Strategy for further details. · Scored peer review criteria include Clinical Impact; Research Strategy and Feasibility; Recruitment, Accrual, Retention; Regulatory Strategy and Transition Plan; Statistical Plan and Data Analysis; Ethical Considerations; Personnel and Communication. · Programmatic review criteria include adherence to the intent of the CTA, contribution to program portfolio, relative impact and relevance to military health. https://cdmrp.health.mil/pubs/press/2026/vrppreann
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from Teresa M Parker-Reeser Grants Officer.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before November 12, 2026, allowing time for registration and validation.
Related grant opportunities
- DoW Spinal Cord Injury, Investigator-Initiated Research Award
- ROSES 2025: C.2 Solar System Science
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.